A $3{ imes}2$ crossover design is considered for the bioequivalence of two test formulations with a control. It could be considered as a better choice over $3{ imes}3$ crossover design because of the cost and experimental duration. Oh et al.(1998) derived $3{ imes}2$ crossover design and discussed its benefits over the typical crossover designs. We consider here the statistical models for $3{ imes}2$ crossover design and show its statistical properties. The statistical procedures for the bioequivalence in $3{ imes}2$ crossover design are shown through an example and the results are summarized by satisfying the 3 standards that proposed by the Korea Food and Drug Administration Guidelines for Bioequivalence.